# 2025-11754: FDA Offers Companies a Remote Checkup Instead of an Inspection

2025-11754, Conducting Remote Regulatory Assessments-Questions and Answers; Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-06-26, effective 2025-06-26; PRIA reads it as touching household money (as of 2026-11-05).

- Canonical: https://policyrisk.com/federal-register/2025-11754
- As of: 2026-11-05
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-11754
- Title: Conducting Remote Regulatory Assessments-Questions and Answers; Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 27319
- Published: 2025-06-26
- Effective: 2025-06-26
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-05

## In one line

FDA Offers Companies a Remote Checkup Instead of an Inspection

## Summary

The FDA just released clear guidance on how they’ll do remote regulatory assessments (RRAs) to check on products without visiting in person. This helps companies that make FDA-regulated products by making inspections easier and faster, especially during public health needs. The new rules start now, and businesses should get ready to work with remote checks, which could save time and money.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Conducting Remote Regulatory Assessments--Question and Answers." The final guidance describes FDA's current thinking regarding its use of remote regulatory assessments (RRAs) and provides answers to frequently asked questions. FDA has used RRAs to conduct oversight, mitigate risk, meet critical public health needs, and help evaluate compliance of FDA- regulated products with applicable regulatory requirements.

## Effects PRIA read

- FDA issues final RRA guidance: benefit, low. On June 26, 2025, the FDA published a final guidance titled "Conducting Remote Regulatory Assessments—Questions and Answers" that describes the Agency's current thinking on using remote regulatory assessments (RRAs) for FDA-regulated products. The guidance replaces a revised draft from January 26,…
- Mandatory records requests expand to devices and BIMO: cost, medium. The guidance aligns with 2022 changes in law (the Food and Drug Omnibus Reform Act of 2022) that added device establishments and sites subject to bioresearch monitoring (BIMO) inspections to FDA's mandatory records-request authority under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Ac…
- Voluntary vs mandatory RRA participation clarified: benefit, low. The final guidance explicitly distinguishes between mandatory and voluntary RRAs and clarifies how FDA intends to inform establishments of the terms of participation in voluntary RRAs and obtain their consent. This explains the process firms can expect when FDA offers a voluntary remote assessment.
- Electronic records and live data access rules clarified: mixed, medium. The guidance clarifies mechanisms for electronic records reviews and the conditions under which FDA might access live data during a remote regulatory assessment, and it addresses concerns about confidentiality and security of establishment information reviewed by FDA. These points explain how and w…
- No Paperwork Reduction Act clearance required: benefit, low. The final guidance states it contains no collection of information and therefore does not require clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995. This means the guidance itself does not impose a new OMB information-collection burden.
- FDA characterizes guidance as deregulatory: benefit, low. The FDA states that, after considering Executive Order 14192 and OMB guidance M-25-20, it finds this action to be deregulatory in nature. The Agency frames the final guidance as reducing regulatory burden in some manner.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-11754 on federalregister.gov](https://www.federalregister.gov/documents/2025/06/26/2025-11754/conducting-remote-regulatory-assessments-questions-and-answers-guidance-for-industry-availability)
- [2025-11754 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-06-26/pdf/2025-11754.pdf)

## Related
- [Previous: 2025-11753, Carbon and Alloy Steel Threaded Rod From India, Taiwan, Thailand, and the Peopl…](https://policyrisk.com/federal-register/2025-11753)
- [Next: 2025-11757, Homeland Security Advisory Council; Notice of Meeting](https://policyrisk.com/federal-register/2025-11757)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-11754 (as of 2026-11-05).
